Howard Grossman, M.D.
Howard Grossman is a board-certified internist with a private practice in Manhattan. He is a general practitioner, but is most widely known as a specialist in HIV medicine. His work with people affected by HIV lead him to become one of the plaintiffs in the landmark suit Vacco v. Quill, et al., which sought to overturn laws preventing terminally-ill patients from obtaining their physicians' help to end their own lives. The case was decided in 1997, with the Supreme Court finding no constitutional guarantee of "the right to die," but leaving the door open for states to experiment with various options. Dr. Grossman earned a B.A. in political science at Haverford College and studied medicine at SUNY Downstate College of Medicine in Brooklyn. He did his residency at Kings County Hospital, one of the largest public hospitals in Brooklyn. It was there that he saw some of the first cases of AIDS in the early 1980s. Dr. Grossman worked at St. Clare's Hospital, at the first dedicated AIDS unit in the country and entered private practice in 1987. He has one of the largest HIV practices in New York and serves a diverse patient population. Dr. Grossman is an Assistant Attending Physician at St. Luke's-Roosevelt Hospital Center in Manhattan and is an Associate Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons. He has become nationally recognized as an educator on HIV and as an advocate for gay and lesbian civil rights and the rights of People with HIV. Dr. Grossman has served as a consultant to many pharmaceutical companies including Glaxo-Wellcome, Abbott, Hoffman-LaRoche, Ortho Biotech, Janssen, Agouron and Bristol-Myers Squibb. He has also worked with government panels at the National Institutes of Health and the Food and Drug Administration. Dr. Grossman has been involved with multiple community-based organizations and has served on the boards of the Gay Men's Health Crisis and the People with AIDS Health Group. He is actively involved with the Treatment Activists Group (TAG), a group which has had a profound impact on drug development and availability.
Latest by Howard Grossman, M.D.
"I am a proud gay man, devoted to HIV treatment and a staunch advocate for sexual freedom and for PrEP," writes Dr. Grossman. "And I am beginning to get freaked out about the tidal wave of STIs I'm seeing in my practice."
PrEP is a game-changer in so many ways. One of the biggest changes is that we can reasonably start looking at risk in various types of sexual encounters. With real data, we can help people to begin to think about their risk in very clear ways.
The Change in Risk of Clinical Progression after Initiation of HAART: The EuroSIDA Study Slide Session 1905 Authored by J.D. Lundgren, A. Mocroft, J.M. Gatell, O. Kirk, C. Katlama, S. Vella, A.N. Phillips The EuroSIDA study is a long-term ...